Supplementation by ketosteril

Phase 2

CCentre Hospitalier le Mans

Supplementation by ketosteril is one of 4 therapeutic programs targeting Haemodialysis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HaemodialysisNot yet recruiting

HaemodialysisPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Haemodialysis

#DrugCompanyPhaseTrials

Oxlumo

Alnylam Pharmaceuticals

Phase 2

1 2

Colcrys

Jazz Pharmaceuticals

Preclinical

1 3

Supplementation by ketosteril

CCentre Hospitalier le Mans

Phase 2

1 4

Slow Sodium

SSt George's, University of London

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Not yet recruiting

Haemodialysis

NCT07699627

Clinical

Trials by Indication[1]

Haemodialysis1 trial

INCREDIBLE: INCREmental DIalysis and Diet for a Better Life Experience; Clinical Relevance of an "add-on" Ketosteril Supplementation on Incremental Haemodialysis Period in Incident Haemodialysis Patients. An Exploratory Randomized Controlled Trial

Not yet recruiting·CCentre Hospitalier le Mans·Phase 2·NCT07699627·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Supplementation by ketosteril. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Supplementation by ketosteril. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Centre Hospitalier le Mans company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCentre Hospitalier le Mans

Supplementation by ketosteril

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Haemodialysis1 trial

References

Drug Info

Quick Facts

Related News